{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:08:29Z","timestamp":1792145309149,"version":"4.4.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients. We describe the case of a patient who presented with a large HCC in the left liver associated with portal vein thrombosis (PVT). After 9 months of sorafenib treatment, reassessment showed that the tumors had decreased in size with recanalization of the portal vein. A lateral left hepatectomy was performed and pathology showed complete necrosis of the tumor. Sorafenib can downstage HCC in patients with cirrhosis allowing further surgical resection.<\/jats:p>","DOI":"10.1186\/1477-7819-11-171","type":"journal-article","created":{"date-parts":[[2013,8,2]],"date-time":"2013-08-02T16:13:58Z","timestamp":1375460038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib"],"prefix":"10.1186","volume":"11","author":[{"given":"Sabrina","family":"Kermiche-Rahali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Di Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Drieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Di Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Scott\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,2]]},"reference":[{"key":"1373_CR1","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","volume":"362","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet. 2003, 362: 1907-1917. 10.1016\/S0140-6736(03)14964-1.","journal-title":"Lancet"},{"key":"1373_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","volume":"35","author":"J Bruix","year":"2001","unstructured":"Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rod\u00e9s J, EASL Panel of Experts on HCC: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001, 35: 421-430. 10.1016\/S0168-8278(01)00130-1.","journal-title":"J Hepatol"},{"key":"1373_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1053\/jhep.2002.32089","volume":"35","author":"J Bruix","year":"2002","unstructured":"Bruix J, Llovet JM: Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002, 35: 519-524. 10.1053\/jhep.2002.32089.","journal-title":"Hepatology"},{"key":"1373_CR4","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/jnci\/djn134","volume":"100","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ, Panel of Experts in HCC-Design Clinical Trials: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008, 100: 698-711. 10.1093\/jnci\/djn134.","journal-title":"J Natl Cancer Inst"},{"key":"1373_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, H\u00e4ussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008, 359: 378-390. 10.1056\/NEJMoa0708857.","journal-title":"N Engl J Med"},{"key":"1373_CR6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1200\/JCO.2010.32.6785","volume":"20","author":"E Curtit","year":"2011","unstructured":"Curtit E, Thiery-Vuillemin A, Nguyen T, Heyd B, Pivot X, Di Martino V, Borg C: Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report. J Clin Oncol. 2011, 20: 330-332.","journal-title":"J Clin Oncol"},{"key":"1373_CR7","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/hep.20933","volume":"42","author":"J Bruix","year":"2005","unstructured":"Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology. 2005, 42: 1208-1236. 10.1002\/hep.20933.","journal-title":"Hepatology"},{"key":"1373_CR8","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1097\/SLA.0b013e31828329b8","volume":"257","author":"G Torzilli","year":"2013","unstructured":"Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, Vauthey JN, Choti MA, De Santibanes E, Donadon M, Morenghi E, Makuuchi M: A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL\/AASLD recommendations?: an observational study of the HCC East\u2013west study group. Ann Surg. 2013, 257: 929-937. 10.1097\/SLA.0b013e31828329b8.","journal-title":"Ann Surg"},{"key":"1373_CR9","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res. 2004, 64: 7099-7109. 10.1158\/0008-5472.CAN-04-1443.","journal-title":"Cancer Res"},{"key":"1373_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10: 25-34. 10.1016\/S1470-2045(08)70285-7.","journal-title":"Lancet Oncol"},{"key":"1373_CR11","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/j.1478-3231.2010.02441.x","volume":"31","author":"S Irtan","year":"2011","unstructured":"Irtan S, Chopin-Laly X, Ronot M, Faivre S, Paradis V, Belghiti J: Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. Liver Int. 2011, 31: 740-743. 10.1111\/j.1478-3231.2010.02441.x.","journal-title":"Liver Int"},{"key":"1373_CR12","doi-asserted-by":"publisher","first-page":"7910","DOI":"10.4061\/2011\/791013","volume":"2011","author":"L Barbier","year":"2011","unstructured":"Barbier L, Muscari F, Le Guellec S, Pariente A, Otal P, Suc B: Liver resection after downstaging hepatocellular carcinoma with sorafenib. Int J Hepatol. 2011, 2011: 7910-7913.","journal-title":"Int J Hepatol"},{"key":"1373_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00261-005-0150-x","volume":"31","author":"L Tarantino","year":"2006","unstructured":"Tarantino L, Francica G, Sordelli I, Esposito F, Giorgio A, Sorrentino P, de Stefano G, Di Sarno A, Ferraioli G, Sperlongano P: Diagnosis of benign and malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma: color Doppler US, contrast-enhanced US, and fine needle biopsy. Abdom Imaging. 2006, 31: 537-544. 10.1007\/s00261-005-0150-x.","journal-title":"Abdom Imaging"},{"key":"1373_CR14","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/lt.22101","volume":"16","author":"F Piscaglia","year":"2010","unstructured":"Piscaglia F, Gianstefani A, Ravaioli M, Golfieri R, Cappelli A, Giampalma E, Sagrini E, Imbriaco G, Pinna AD, Bolondi L, Bologna Liver Transplant Group: Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. Liver Transpl. 2010, 16: 658-667.","journal-title":"Liver Transpl"},{"key":"1373_CR15","first-page":"403","volume":"25","author":"Q Li","year":"2006","unstructured":"Li Q, Xu B, Fu L, Hao XS: Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma. J Exp Clin Cancer Res. 2006, 25: 403-409.","journal-title":"J Exp Clin Cancer Res"},{"key":"1373_CR16","volume-title":"Ann Surg Oncol","author":"L Barbier","year":"2013","unstructured":"Barbier L, Fuks D, Pessaux P, Muscari F, Le Treut YP, Faivre S, Belghiti J: Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study. Ann Surg Oncol. 2013, 10.1245\/s10434-013-3029-z."}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7819-11-171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T01:08:27Z","timestamp":1630544907000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/1477-7819-11-171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,2]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1373"],"URL":"https:\/\/doi.org\/10.1186\/1477-7819-11-171","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,2]]},"assertion":[{"value":"14 May 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"171"}}